Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation.

Roan JN, Chou CH, Hsu CH, Wu SY, Huang YC, Yang YJ, Luo CY.

Ann Transplant. 2013 Feb 5;18:43-52. doi: 10.12659/AOT.883812.

PMID:
23792500
3.

AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.

van Agteren M, Armstrong VW, van Schaik RH, de Fijter H, Hartmann A, Zeier M, Budde K, Kuypers D, Pisarski P, Le Meur Y, van der Werf M, Mamelok RD, Oellerich M, van Gelder T.

Ther Drug Monit. 2008 Aug;30(4):439-44. doi: 10.1097/FTD.0b013e318180c709.

PMID:
18641546
5.

Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.

Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.

J Clin Pharm Ther. 2006 Feb;31(1):27-34.

PMID:
16476117
6.

Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses.

Kamar N, Marquet P, Gandia P, Muscari F, Lavayssière L, Esposito L, Guitard J, Canivet C, Peron JM, Alric L, Suc B, Saint-Marcoux F, Rostaing L.

Ther Drug Monit. 2009 Aug;31(4):451-6. doi: 10.1097/FTD.0b013e3181aa776e.

PMID:
19531983
7.

Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.

Kuypers DR, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, Vanrenterghem Y.

Clin Ther. 2008 Apr;30(4):673-83.

PMID:
18498916
8.

Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.

Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.

Transpl Immunol. 1997 Sep;5(3):225-32.

PMID:
9402690
9.

Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.

Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, Daems J.

Ther Drug Monit. 2003 Oct;25(5):609-22.

PMID:
14508385
10.

Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.

Dipchand AI, Pietra B, McCrindle BW, Rosebrook-Bicknell HL, Boucek MM.

J Heart Lung Transplant. 2001 Oct;20(10):1035-43.

PMID:
11595558
11.

Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.

Kaczmarek I, Bigdeli AK, Vogeser M, Mueller T, Beiras-Fernandez A, Kaczmarek P, Schmoeckel M, Meiser B, Reichart B, Ueberfuhr P.

Ther Drug Monit. 2008 Aug;30(4):419-27. doi: 10.1097/FTD.0b013e31817d7064.

PMID:
18641552
12.

Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.

Mardigyan V, Tchervenkov J, Metrakos P, Barkun J, Deschenes M, Cantarovich M.

Clin Ther. 2005 Apr;27(4):463-9.

PMID:
15922819
13.
14.

Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.

Nashan B, Saliba F, Durand F, Barcéna R, Herrero JI, Mentha G, Neuhaus P, Bowles M, Patch D, Bernardos A, Klempnauer J, Bouw R, Ives J, Mamelok R, McKay D, Truman M, Marotta P.

Liver Transpl. 2009 Feb;15(2):136-47. doi: 10.1002/lt.21657.

15.

Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.

Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, Squifflet JP, Wallemacq P.

Clin Chem. 2001;47(7):1241-8.

16.

The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.

Gourishankar S, Houde I, Keown PA, Landsberg D, Cardella CJ, Barama AA, Dandavino R, Shoker A, Pirc L, Wrobel MM, Kiberd BA.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1282-9. doi: 10.2215/CJN.09091209. Epub 2010 May 24.

17.

Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.

Merkel U, Lindner S, Vollandt R, Sperschneider H, Balogh A.

Int J Clin Pharmacol Ther. 2005 Aug;43(8):379-88.

PMID:
16119513
18.

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hené RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ.

Transplantation. 1999 Jul 27;68(2):261-6.

PMID:
10440399
19.

Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.

Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, Squifflet JP, Wallemacq P.

Clin Chem. 2001 Jan;47(1):88-94.

20.

Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.

J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):541-64. doi: 10.1007/s10928-009-9136-6. Epub 2009 Nov 11.

Supplemental Content

Support Center